Literature DB >> 7642685

Biotherapy of cancer. Perspectives of immunotherapy and gene therapy.

V Schirrmacher1.   

Abstract

Prospects for a new biologically based strategy of cancer treatment are being discussed. While physically and chemically based therapies, such as radio- and chemotherapy, are not directed against cancer tissue only and have a suppressive effect on the immune system, immunotherapy and gene therapy, which are discussed here, try to be more selective and to stimulate rather than suppress antitumor immune mechanisms. On the basis of personal experience with these new technologies, good future prospects are predicted for the application of cancer vaccines and immune T lymphocytes for active specific immunization (ASI) and adoptive immunotherapy (ADI) respectively. While ASI strategies aim at micrometastases being affected by activated host immune T cells, and might find a place for postoperative adjuvant treatment in high-risk cancer patients, cellular therapies such as ADI do not require an intact host immune system and could therefore also find application in advanced stages of disease. In spite of the exciting new perspectives of immuno- and gene therapy for the cancer patient, this therapy is not yet a defined discipline and requires years of further research.

Entities:  

Mesh:

Year:  1995        PMID: 7642685     DOI: 10.1007/bf01218359

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  41 in total

1.  A cell culture model for T lymphocyte clonal anergy.

Authors:  R H Schwartz
Journal:  Science       Date:  1990-06-15       Impact factor: 47.728

2.  IL-2 and gene-therapy of cancer.

Authors:  J Bubenik
Journal:  Int J Oncol       Date:  1993-06       Impact factor: 5.650

3.  Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion.

Authors:  J M Goldman; R P Gale; M M Horowitz; J C Biggs; R E Champlin; E Gluckman; R G Hoffmann; S J Jacobsen; A M Marmont; P B McGlave
Journal:  Ann Intern Med       Date:  1988-06       Impact factor: 25.391

4.  Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response.

Authors:  E R Fearon; D M Pardoll; T Itaya; P Golumbek; H I Levitsky; J W Simons; H Karasuyama; B Vogelstein; P Frost
Journal:  Cell       Date:  1990-02-09       Impact factor: 41.582

5.  Viral hemagglutinin augments peptide-specific cytotoxic T cell responses.

Authors:  C Ertel; N S Millar; P T Emmerson; V Schirrmacher; P von Hoegen
Journal:  Eur J Immunol       Date:  1993-10       Impact factor: 5.532

6.  Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer.

Authors:  S A Rosenberg; M T Lotze; J C Yang; S L Topalian; A E Chang; D J Schwartzentruber; P Aebersold; S Leitman; W M Linehan; C A Seipp
Journal:  J Natl Cancer Inst       Date:  1993-04-21       Impact factor: 13.506

7.  Clinical trial of recombinant leukocyte A interferon as initial therapy for favorable histology non-Hodgkin's lymphomas and chronic lymphocytic leukemia. An Eastern Cooperative Oncology Group pilot study.

Authors:  M J O'Connell; J P Colgan; M M Oken; R E Ritts; N E Kay; L M Itri
Journal:  J Clin Oncol       Date:  1986-02       Impact factor: 44.544

Review 8.  Leukemia: management of relapse after allogeneic bone marrow transplantation.

Authors:  L Kumar
Journal:  J Clin Oncol       Date:  1994-08       Impact factor: 44.544

9.  Effective anti-metastatic melanoma vaccination with tumor cells transfected with MHC genes and/or infected with Newcastle disease virus (NDV).

Authors:  D Plaksin; A Porgador; E Vadai; M Feldman; V Schirrmacher; L Eisenbach
Journal:  Int J Cancer       Date:  1994-12-15       Impact factor: 7.396

10.  In vitro and clinical characterisation of a Newcastle disease virus-modified autologous tumour cell vaccine for treatment of colorectal cancer patients.

Authors:  W Liebrich; P Schlag; M Manasterski; B Lehner; M Stöhr; P Möller; V Schirrmacher
Journal:  Eur J Cancer       Date:  1991       Impact factor: 9.162

View more
  3 in total

1.  Intraoperative subcutaneous or intrasplenic vaccination with modified autologous tumor cells leads to enhanced survival in a mouse tumor model.

Authors:  Arne Dietrich; Christoph Stockmar; Gabriela Aust; Susan Endesfelder; Anke Guetz; Ulrich Sack; Manfred Schoenfelder; Johann Hauss
Journal:  J Cancer Res Clin Oncol       Date:  2006-01-04       Impact factor: 4.553

2.  Effectiveness of a simply designed tumor vaccine in prevention of malignant melanoma development.

Authors:  S Novaković; A Ihan; B Jezersek
Journal:  Jpn J Cancer Res       Date:  1999-10

Review 3.  Dendritic Polymers for Theranostics.

Authors:  Yuan Ma; Quanbing Mou; Dali Wang; Xinyuan Zhu; Deyue Yan
Journal:  Theranostics       Date:  2016-04-27       Impact factor: 11.556

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.